Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1995 Oct;39(10):2316–2319. doi: 10.1128/aac.39.10.2316

Treatment of Mycobacterium haemophilum infection in a murine model with clarithromycin, rifabutin, and ciprofloxacin.

B A Atkinson 1, R Bocanegra 1, J R Graybill 1
PMCID: PMC162935  PMID: 8619588

Abstract

An animal model of disseminated Mycobacterium haemophilum infection was utilized to compare treatment with azithromycin, ciprofloxacin, rifabutin, and the combination of clarithromycin with rifabutin. Following subcutaneous challenge with M. haemophilum, local and disseminated infection occurred only in immunosuppressed mice. For disseminated infection, ciprofloxacin was relatively ineffective therapy. Clarithromycin and rifabutin alone significantly reduced the tissue burden in the spleen after 4 weeks of therapy. Combination therapy with rifabutin and clarithromycin was superior to 4 weeks of treatment with the individual agents. When immunosuppressed mice were treated for 20 weeks with the combination of rifabutin and clarithromycin, the tissue burden remained reduced in the spleen at 1 month following the completion of therapy. Combined rifabutin and clarithromycin provide effective treatment for M. haemophilum in this model.

Full Text

The Full Text of this article is available as a PDF (256.8 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abbott M. R., Smith D. D. The pathogenic effects of Mycobacterium haemophilum in immunosuppressed albino mice. J Med Microbiol. 1980 Nov;13(4):535–540. doi: 10.1099/00222615-13-4-535. [DOI] [PubMed] [Google Scholar]
  2. Davis B. R., Brumbach J., Sanders W. J., Wolinsky E. Skin lesions caused by Mycobacterium haemophilum. Ann Intern Med. 1982 Nov;97(5):723–724. doi: 10.7326/0003-4819-97-5-723. [DOI] [PubMed] [Google Scholar]
  3. Dawson D. J., Jennis F. Mycobacteria with a growth requirement for ferric ammonium citrate, identified as Mycobacterium haemophilum. J Clin Microbiol. 1980 Feb;11(2):190–192. doi: 10.1128/jcm.11.2.190-192.1980. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Dever L. L., Martin J. W., Seaworth B., Jorgensen J. H. Varied presentations and responses to treatment of infections caused by Mycobacterium haemophilum in patients with AIDS. Clin Infect Dis. 1992 Jun;14(6):1195–1200. doi: 10.1093/clinids/14.6.1195. [DOI] [PubMed] [Google Scholar]
  5. Kiehn T. E., White M., Pursell K. J., Boone N., Tsivitis M., Brown A. E., Polsky B., Armstrong D. A cluster of four cases of Mycobacterium haemophilum infection. Eur J Clin Microbiol Infect Dis. 1993 Feb;12(2):114–118. doi: 10.1007/BF01967586. [DOI] [PubMed] [Google Scholar]
  6. Kristjansson M., Bieluch V. M., Byeff P. D. Mycobacterium haemophilum infection in immunocompromised patients: case report and review of the literature. Rev Infect Dis. 1991 Sep-Oct;13(5):906–910. doi: 10.1093/clinids/13.5.906. [DOI] [PubMed] [Google Scholar]
  7. Males B. M., West T. E., Bartholomew W. R. Mycobacterium haemophilum infection in a patient with acquired immune deficiency syndrome. J Clin Microbiol. 1987 Jan;25(1):186–190. doi: 10.1128/jcm.25.1.186-190.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. McBride J. A., McBride M. E., Wolf J. E., Jr Evaluation of commercial blood-containing media for cultivation of Mycobacterium haemophilum. Am J Clin Pathol. 1992 Sep;98(3):282–286. doi: 10.1093/ajcp/98.3.282. [DOI] [PubMed] [Google Scholar]
  9. McBride M. E., Rudolph A. H., Tschen J. A., Cernoch P., Davis J., Brown B. A., Wallace R. J., Jr Diagnostic and therapeutic considerations for cutaneous Mycobacterium haemophilum infections. Arch Dermatol. 1991 Feb;127(2):276–277. [PubMed] [Google Scholar]
  10. McGovern J., Bix B. C., Webster G. Mycobacterium haemophilum skin disease successfully treated with excision. J Am Acad Dermatol. 1994 Feb;30(2 Pt 1):269–270. doi: 10.1016/s0190-9622(08)81925-1. [DOI] [PubMed] [Google Scholar]
  11. Soubani A. O., al-Marri M., Forlenza S. Successful treatment of disseminated Mycobacterium haemophilum infection in a patient with AIDS. Clin Infect Dis. 1994 Mar;18(3):475–476. doi: 10.1093/clinids/18.3.475. [DOI] [PubMed] [Google Scholar]
  12. Straus W. L., Ostroff S. M., Jernigan D. B., Kiehn T. E., Sordillo E. M., Armstrong D., Boone N., Schneider N., Kilburn J. O., Silcox V. A. Clinical and epidemiologic characteristics of Mycobacterium haemophilum, an emerging pathogen in immunocompromised patients. Ann Intern Med. 1994 Jan 15;120(2):118–125. doi: 10.7326/0003-4819-120-2-199401150-00004. [DOI] [PubMed] [Google Scholar]
  13. Vadney F. S., Hawkins J. E. Evaluation of a simple method for growing Mycobacterium haemophilum. J Clin Microbiol. 1985 Nov;22(5):884–885. doi: 10.1128/jcm.22.5.884-885.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Yarrish R. L., Shay W., LaBombardi V. J., Meyerson M., Miller D. K., Larone D. Osteomyelitis caused by Mycobacterium haemophilum: successful therapy in two patients with AIDS. AIDS. 1992 Jun;6(6):557–561. [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES